Cutaneous leishmaniasis: progress towards a vaccine. - Wikidata - wikimedia - TriplyDB

Cutaneous leishmaniasis: progress towards a vaccine.

Cutaneous leishmaniasis: progress towards a vaccine.

http://www.wikidata.org/entity/Q37290119

about

Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity Vector transmission of leishmania abrogates vaccine-induced protective immunity Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen Changes in membrane fluid state and heat shock response cause attenuation of virulence The biology and control of leishmaniasis vectors.TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.Immune and biochemical responses in skin differ between bovine hosts genetically susceptible and resistant to the cattle tick Rhipicephalus microplus An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.An evolutionary analysis of trypanosomatid GP63 proteases.

P2860

Q27312070-7D69762E-7161-4484-B85F-D885C5316A20 Q27316727-78AD165F-61F0-4C7C-9742-70767339A45C Q28541600-625CA316-1E87-49C1-9B21-E6C597F02FE8 Q33725405-7AA46C97-27C8-4881-B12B-6D2385BAE116 Q33929838-9382991D-E1DB-4AF9-9F16-3AC538D0084D Q33939303-6EBCF434-B50F-41E7-8C39-9B6E03533B2F Q34533591-D56A852F-C646-45D4-BFCB-72B4B310CFA2 Q37615852-A7870A72-5E8A-4EF0-A856-DA5735109DEA Q39156596-56712B84-9F17-446C-9B91-E384E7E450E8 Q52718974-FF7D8873-8648-4209-89B7-66B8B939EF5C

P2860

Cutaneous leishmaniasis: progress towards a vaccine.

http://www.wikidata.org/entity/Q37290119

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cutaneous leishmaniasis: progress towards a vaccine.

@en

Cutaneous leishmaniasis: progress towards a vaccine.

@nl

type

label

Cutaneous leishmaniasis: progress towards a vaccine.

@en

Cutaneous leishmaniasis: progress towards a vaccine.

@nl

prefLabel

Cutaneous leishmaniasis: progress towards a vaccine.

@en

Cutaneous leishmaniasis: progress towards a vaccine.

@nl

P1433

Q37290119-298F1603-2469-4E5A-B99F-D01EDA28F696

P1476

Q37290119-79BAC44F-344B-4EEF-9476-BB676FF2D0E7

P2093

Q37290119-8D8549B1-B795-425A-84BB-1487F2EB5864

Q37290119-FDD885F3-D42D-474A-8669-790D897E9142

P2860

Q37290119-045B1F22-0B6D-4D08-AF1D-2D8DA46056D6

Q37290119-069996CE-1BA3-4334-B6C8-2F6A76EAB1EF

Q37290119-0839C0B9-2F77-40C8-A600-BEEDD5552C23

Q37290119-0866575A-2953-49C0-B3C8-C3E8138FBB7A

Q37290119-113C346D-60CF-4BD4-9E79-41DA0BA5761C

Q37290119-1AB79F00-4A7C-4965-976D-A1DB0DA1B540

Q37290119-29E9B279-2799-489B-A037-10B66A1A5230

Q37290119-2EDE6590-2107-4BBB-94F9-0E39D42618B3

Q37290119-32938691-0A95-4324-8CFF-5A5B40ADB0E7

Q37290119-353DDE81-5CBD-4FB4-AE37-9AA73A031D56

P304

Q37290119-8887A1DE-57F3-4E83-A28B-A3D63A232C0C

P31

Q37290119-5A797964-6F53-4083-B878-3A27CD8DEEF5

P356

Q37290119-7CDB75C8-42CF-49CF-B840-303078BDE555

P433

Q37290119-1A14B444-B770-4514-907F-AB6274005405

P478

Q37290119-837D9D8E-0251-4D59-B623-987E6A8A40FF

P50

Q37290119-54D651E6-BDE6-4D92-9BEA-E57DE8E11EE4

P577

Q37290119-C7FE5E96-15DF-40FD-95C7-0871E673E57C

P698

Q37290119-5137EAEB-BEDF-49FB-A345-E2AFA892BAE4

P356

14760584.7.8.1277

P1433

Expert Review of Vaccines

P1476

Cutaneous leishmaniasis: progress towards a vaccine.

@en

P2093

Marie-Paul Kieny

http://www.w3.org/2001/XMLSchema#string

Pascal Launois

http://www.w3.org/2001/XMLSchema#string

P2860

Leishmania/HIV co-infections: epidemiology in Europe.

Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.

Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva.

Development of a safe live Leishmania vaccine line by gene replacement.

Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major.

Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.

Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice

P304

1277-1287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14760584.7.8.1277

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Fabienne Tacchini-Cottier

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18844599

http://www.w3.org/2001/XMLSchema#string